GSK, the FTSE-100 prescribed drugs big, has poached Burberry Group’s finance chief to create a uncommon all-female govt management group in London’s blue-chip share index.
Sky News has learnt that GSK may announce as quickly as Monday morning that it has recruited Julie Brown to exchange Iain Mackay, who has served as its chief monetary officer since 2019.
The appointment of Ms Brown comes throughout a interval of seismic change for GSK, which demerged its client healthcare enterprise – now known as Haleon – in a £30bn deal in July.
The firm’s new CFO will arrive after almost six years at Burberry, the posh items model, however is a seasoned prescribed drugs trade govt.
Ms Brown was interim group CFO of AstraZeneca and held a lot of different senior roles at GSK’s FTSE-100 rival, in addition to holding the CFO function at Smith & Nephew, the medical gadgets maker.
She can also be a non-executive director of Roche Holding, the Swiss healthcare group, from which she is prone to should step down on account of her GSK appointment.
Under Boris Johnson’s administration, she was additionally a member of the prime minister’s enterprise council, which suggested him on enterprise and financial points.
At GSK, Ms Brown will group up with Dame Emma Walmsley, its chief govt.
Her new employer, which has a market capitalisation of over £53bn, is much bigger than Burberry, which is valued by the inventory market at £6.4bn.
At a capital markets day in June final yr, GSK dedicated to a minimum of 5% gross sales progress and a minimum of 10% working revenue progress over the following 5 years, and an annual gross sales goal of a minimum of £33bn by 2031.
GSK declined to touch upon Saturday.
Source: information.sky.com”